September 17, 2021
Cabometyx® (cabozantinib) is now U.S. FDA approved for to treat patients at least 12 years old who are radioactive iodine-refractory (unresponsive to treatment) or ineligible and have locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy.
- First FDA-approved in 2012, Cabometyx is also indicated to treat renal cell carcinoma and hepatocellular carcinoma in patients who meet certain
- Recommended dosing under the DTC indication is 40mg once daily for pediatric patients who have a body surface area of less than 1.2m2 and 60mg once daily for all other DTC
- Manufactured by Exelixis, , Cabometyx is an oral tablet that should be taken at least one hour before and two hours after eating.